Virax Biolabs Group Limited Ordinary Shares (VRAX) — Financial Flexibility Index

Latest as of September 2025: -4.34x

Virax Biolabs Group Limited Ordinary Shares (VRAX) has a Financial Flexibility Index of -4.34x as of September 2025. Free cash flow of $-2.78 Million (operating CF $-2.92 Million minus capex $141.50K) represents -4% of total liabilities ($641.52K). Also explore VRAX year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-4.34x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-2.78 Million
Operating CF − Capex

Total Liabilities

$641.52K
USD

Capital Expenditures

$141.50K
USD

Virax Biolabs Group Limited Ordinary Shares Financial Flexibility Index (2020–2025)

Historical Financial Flexibility Index trend for Virax Biolabs Group Limited Ordinary Shares across 6 annual periods. Check Virax Biolabs Group Limited Ordinary Sha liquidity resilience to evaluate the company's liquid asset resilience ratio.

Annual Financial Flexibility Index for Virax Biolabs Group Limited Ordinary Shares (2020–2025)

Year-by-year free cash flow to debt coverage for Virax Biolabs Group Limited Ordinary Shares. For the full company profile including market capitalisation, see market value of Virax Biolabs Group Limited Ordinary Sha.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -4.10x $-3.96 Million $-4.56 Million $964.75K ▲ +72.1%
2024 -14.72x $-5.08 Million $-6.25 Million $345.19K ▼ -234.3%
2023 -4.40x $-4.00 Million $-4.18 Million $908.40K ▼ -578.0%
2022 -0.65x $-809.07K $-809.07K $1.25 Million ▲ +4.1%
2021 -0.68x $-590.19K $-590.19K $871.43K ▼ -12.6%
2020 -0.60x $-744.61K $-744.61K $1.24 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities